The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Up to date medical information from GOBLET Cohort 4 demonstrated exercise with the mixture remedy Reolysin (pelareorep) plus Tecentriq (atezolizumab) in sufferers...
A pair of prostate most cancers survivors from the Atlanta space, who've discovered friendship and group collectively, are sharing insights for fellow...
Bettering equitable entry to genomics-based medical trials stays a essential precedence in most cancers care, in keeping with Dr. Nadine A. Jackson,...
